NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer

NCT00675012 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Colon Cancer

Interventions

DRUG: NGR-hTNF
DRUG: Oxaliplatin
DRUG: capecitabine

Sponsor

AGC Biologics S.p.A.